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Notch signaling pathways modulate various cellular processes, including cell proliferation, 
differentiation, adhesion, and communication. Recent studies have demonstrated that Notch1 
signaling also regulates hepatic glucose production and lipid synthesis. However, the effect of Notch1 
signaling on hepatic lipid oxidation has not yet been directly investigated. To define the function of 
Notch1 signaling in hepatic lipid metabolism, wild type mice and Notch1 deficient antisense transgenic 
(NAS) mice were fed a high-fat diet. High-fat diet -fed NAS mice exhibited a marked reduction in 
hepatic triacylglycerol accumulation compared with wild type obese mice. The improved fatty liver was 
associated with an increased expression of hepatic genes involved in fatty acid oxidation. However, 
lipogenic genes were not differentially expressed in the NAS liver, suggesting lipolytic-specific 
regulatory effects by Notch1 signaling. Expression of fatty acid oxidative genes and the rate of fatty 
acid oxidation were also increased by inhibition of Notch1 signaling in HepG2 cells. In addition, similar 
regulatory effects on lipid accumulation were observed in adipocytes. Taken together, these data show 
that inhibition of Notch1 signaling can regulate the expression of fatty acid oxidation genes and may 
provide therapeutic strategies in obesity-induced hepatic steatosis.
The worldwide increase in obesity is the leading cause of metabolic syndrome1,2. Excess accumulation of tria-
cylglycerols and cholesterol in obesity can impede insulin signaling and cause cardiovascular diseases. Although 
active investigation into the etiology of and therapeutic interventions for obesity are in progress, better therapeu-
tic strategies for obesity and its related metabolic syndromes still remain to be elucidated1,3,4.
Adipogenesis is determined by a cascade of transcriptional regulators and a number of signaling pathways 
including Wnt, Hedgehog, BMP, TGF-β , and Notch5–7. Activation of the Wnt, Hedgehog, and TGF-β signaling 
pathways have been shown to stimulate adipogenesis and adipocyte differentiation8. Activation of BMP signaling 
can promote adipocyte differentiation8. Activation of these pathways is relatively clear, however, the role of Notch 
signaling in the control of adipogenesis remains unclear.
Notch signaling is a conserved pathway that regulates cell proliferation, differentiation, self renewal poten-
tial, apoptosis, inflammatory response, and cell-fate decision9–12. Notch signaling pathways are complex and 
involve four Notch receptors and five ligands of the Jagged/Delta-like families. Activated Notch receptors by 
cognate interaction with ligands can lead to cleavage, release, and nuclear entry of the Notch intracellular domain 
(NICD). In the nucleus, activated NICD induces transcription of target genes such as Hairy enhancer of split 
(HES) and the Hes-related (Hey) family13. Recent studies have shown that Notch1 signaling also regulates 
hepatic glucose and lipid accumulation. Notch1 haploinsufficiency can increase insulin sensitivity by suppressing 
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glucose 6-phosphatase (G6p) expression in the liver14. Forced expression of NICD1 in the liver increases fatty 
acid synthase (Fas) expression and induces hepatosteatosis, whereas NICD1 increases intestinal lipid accumu-
lation by inducing RPL29 and Abhd1 expression14,15. In addition, recent studies have also shown that inhibition 
of Notch1 signaling in the liver decreases mTorc1 stability, resulting in decreased lipogenesis and protection 
from diet-induced fatty liver13. These results indicate that Notch1 plays a significant role in glucose and lipid 
metabolism.
In the present study, Notch1-deficient Notch1 antisense (NAS) mice were fed a high-fat diet to determine the 
effect of Notch1 signaling on hepatic lipid accumulation and expression of lipogenic and oxidative genes. Our 
data show that inhibition of Notch1 signaling suppresses diet induced hepatic lipid accumulation, likely through 
increased fatty acid oxidation. These data further suggest the diverse but conserved biological actions of Notch1 
signaling in metabolism.
Results
Notch1 expression is increased in obese and diabetic fatty livers. To examine the tissue expres-
sion pattern of Notch1 in mice, real-time PCR was performed. Notch1 expression was highest in the brain, with 
surprisingly similar expression levels in adipose tissues, and modest expression in the lung and liver (Fig. 1A). 
Other tissues also expressed Notch1, although their levels were lower than those of white adipose tissue and brain. 
Consistent with previous data14,16, the strong expression profiles of Notch1 in fat tissues and liver indicate that 
Notch1 may play a significant role in glucose and lipid metabolism. To investigate the potential roles of Notch1 in 
metabolism, Notch1 expression was measured in high-fat diet-fed obese and diabetic mice. Notch1 protein and 
mRNA expression were greatly elevated in the livers of obese mice (Fig. 1B–D). A similar expression pattern was 
detected in the white adipose tissue of obese and diabetic mice (Fig. 1E), suggesting a positive correlation between 
the expression of Notch1 and lipid accumulation and metabolic diseases.
Inhibition of Notch1 signaling prevents insulin resistance in diet-induced obese mice. Earlier 
studies have shown that Notch1 inhibition can improve insulin sensitivity13,14. Therefore, the effects of Notch 
inhibition in diet-induced obese mice were investigated in the present study. Mice overexpressing Notch1 anti-
sense (NAS) under the control of a mouse mammary tumor virus long terminal repeat promoter were generated 
and backcrossed to C57BL/6 mice and characterized as described previously17. NAS mice with defects in Notch1 
expression and downstream signaling have been previously verified by several groups12,18. NAS and wild type 
C57BL/6 mice (C57) were fed a high-fat diet (HFD) and a normal chow control diet (ND) for 12 weeks. The 
inhibition of Notch1 expression in the liver of NAS mice was confirmed by Western blotting (Fig. 2A). Body 
weight was not consistently different between the NAS and control mice (Fig. S1A). Glucose tolerance (GTT) and 
insulin tolerance tests (ITT) confirmed that the insulin sensitivity was significantly (p < 0.05) improved in NAS 
Figure 1. A high-fat diet increases Notch1 expression in liver. (A) Tissue distribution of Notch1 mRNA 
expression in mice; (b,c) Hepatic Notch1 protein expression (B) and quantification (C) in normal diet-fed 
(ND), high-fat diet-fed mice (HFD), and high-fat diet-fed Notch1 antisense transgenic (NAS) mice were 
detected by Western blotting; (D) Hepatic Notch1 mRNA expression was measured by real-time PCR in ND- 
and HFD-fed mice; (E) Notch1 mRNA expression in epididymal fat tissues was measured in HFD obese (upper) 
and diabetic db/db mice (lower). Data shown represent the mean ± SEM (n = 3 or 4 per group). Statistically 
significant differences in protein expression between the control ND-fed C57BL/6 and HFD-fed mice, or 
between non-diabetic C57BL/6 mice (WT) and diabetic (db/db) mice were determined by a Student’s t-test 
(*p < 0.05).
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mice (Fig. 2B,C). Histological analysis of livers showed less lipid accumulation in the HFD-fed NAS mice com-
pared with the control mice (Fig. 2D). Lower serum triacylglycerol levels in NAS mice fed a HFD further suggest 
that Notch1 inhibition prevents hepatic steatosis (Fig. 2E). Consistently, elevated levels of free fatty acids in the 
high-fat diet-fed control mice were significantly (p < 0.05) reduced in NAS mice (Fig. S2). Plasma insulin levels 
and food intake were not significantly (p > 0.05) different between the two groups. However, the plasma glucagon 
level was significantly (p < 0.05) decreased in NAS mice (Fig. S1).
To further verify the effect of Notch1 inhibition on insulin sensitivity, HepG2 cells were induced to an 
insulin-resistant state by treatment with oleic acid, and subsequently treated with the inhibitor of γ -secretase 
(an enzyme that activates Notch signaling) N-[N-(3.5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butylester 
(DAPT) or dibenzazepine (DBZ). Inhibitory effects of DAPT and DBZ on Notch1 signaling were confirmed in 
HepG2 cells (Fig. S3). Insulin treatment under resistant conditions resulted in significantly (p < 0.05) lower levels 
of phosphorylated AKT1 and IRS-1 compared with the levels of phosphorylated AKT1 and IRS-1 under normal 
conditions. Treatment with these inhibitors increased AKT and IRS-1 phosphorylation levels similar to those 
seen in insulin sensitive states, even under insulin-resistant conditions (Fig. 2F).
Inhibition of Notch1 signaling induces hepatic oxidative genes in diet-induced fatty liver. The 
improved fatty liver in diet-induced obese NAS mice could be directly attributed to decreased lipogenesis and/
or increased oxidation. To differentiate between these possibilities, lipogenic and lipolytic genes were measured 
by real-time PCR. The expression of peroxisome proliferator-activated receptor alpha (Pparα), carnitine pal-
mitoyltransferase 1a (Cpt1a), acyl coenzyme A synthetase 1 (Acsl1), acyl coenzyme A oxidase 1 (Aox1), acyl 
coenzyme A thioesterase 1 (Acot1), and uncoupling protein 2 (Ucp2) were significantly (p < 0.05) induced in 
the NAS liver compared with the control (Fig. 3A). In contrast, lipogenic genes including sterol regulatory 
element-binding protein-1c (Srebp-1c), fatty acid synthase (Fas), acetyl coenzyme A carboxylase (Acc), peroxi-
some proliferator-activated receptor gamma (Pparγ), and fatty acid binding protein 4 (aP2) were not differentially 
expressed between NAS and control mice (Fig. 3B,C). Acc protein levels were also similar between the NAS and 
control mice (Fig. S4). Previous studies have shown that Notch1 inhibition can impair gluconeogenesis by sup-
pressing glucose 6-phosphatase (G6p) expression14. Consistent with this finding, we also detected reduced expres-
sion of G6p in the ND-fed group, but no reduction in phosphoenolpyruvate carboxykinase (Pepck) or pyruvate 
carboxylase (Pc) mRNA expression (Fig. 3C). These data suggest the possibility that increased fatty acid oxidation 
may be responsible for the reduced hepatic lipid accumulation in NAS mice. Thus, our findings highlight poten-
tial novel involvement of Notch1 signaling in the regulation of hepatic fatty acid oxidative genes.
Figure 2. Genetic and pharmacological reduction of Notch1 signaling improves insulin sensitivity and 
reduces lipid accumulation in liver cells exposed to obesity-promoting fats. (A) Reduced hepatic Notch1 
expression in NAS mice. Notch1 protein expression from the livers of HFD-fed C57BL/6 (C57) and NAS mice 
was measured by Western blotting. Glucose tolerance (B) and insulin tolerance tests (C) were performed in 
16-hour-fasted C57BL/6 and NAS mice. The mice analyzed were 21-weeks-old, 12 weeks HFD-fed C57BL/6 
and NAS mice (n = 7 of each group); (D) H&E stain of liver sections from C57BL/6 and NAS mice; (E) Serum 
triacylglycerol levels from C57BL/6 (black) and NAS mice (gray) were determined; (F) Western blotting 
analysis of insulin signaling proteins from HepG2 cells. An insulin-resistant state was induced in HepG2 cells by 
treatment with oleic acid and the Notch signaling inhibitors, DAPT and DBZ. Statistically significant differences 
in NAS mice were determined relative to the control mice by a Student’s t-test (*p < 0.05).
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Figure 3. Mice with reduced Notch1 levels exhibit increased expression of genes encoding lipid oxidation 
proteins. (A–C) Hepatic expression of oxidative, lipogenic, and gluconeogenic genes in C57BL/6 and NAS 
mice fed with a normal chow diet (ND) or a high-fat diet (HFD) for 12 weeks. (A) Oxidative genes including 
Pparα, Cpt1, Acsl1, Aox1, Acot1, and Ucp2 in livers of control (C57BL/6) and NAS mice fed with a ND or a 
HFD were measured by real-time PCR (n = 5 of each group); (B) Lipogenic genes such as Srebp-1c, Fas, Acc, 
and Pparγ in livers of control and NAS mice fed with a ND or a HFD were measured by real-time PCR (n = 5); 
(C) Gluconeogenic genes G6p, Pc, Pepck, and aP2 were measured in control and NAS mice fed with a ND or 
a HFD by real-time PCR (n = 5). Data shown represent the mean ± SEM . Statistically significant differences 
in gene expression was determined relative to the control mice by a Student’s t-test (*p < 0.05; **p < 0.005; 
***p < 0.0005).
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Pharmacological and genetic inhibition of Notch1 signaling increases fatty acid oxidation in 
HepG2 cells. The reduced hepatic fatty acid accumulation in NAS mice suggests that Notch1 signaling can 
act in a cell-autonomous manner. To directly test the hypothesis that Notch1 signaling may affect the expression 
of genes involved in hepatic fatty acid oxidation, the human liver cancer cells, HepG2, were treated with DAPT. 
In agreement with our observation in NAS mice, DAPT treatment induced the expression of fatty acid oxidative 
genes such as CPT1A and ACSL1 in a dose-dependent manner. However, G6p expression was suppressed by 
DAPT, and lipogenic genes (FAS, ACC, SREBP-1c) were not differentially expressed (Fig. 4A). To directly test the 
effect of Notch1 inhibition on fatty acid oxidation, HepG2 cells were treated with DAPT and fatty acid oxidation 
was measured using [14C] palmitate. Comparable to the effects of treatment with the PPARα agonist GW7647, 
Notch1 inhibition also increased the rate of fatty acid oxidation (Fig. 4B).
Notch1 receptors are activated upon binding ligands, leading to γ -secretase-dependent generation of NICD1 
followed by translocation to the nucleus and transcription of target genes10,13,19. To further verify the regulation 
of Notch1 on oxidative genes, the activated form of Notch1, NICD1, was transiently expressed in HepG2 cells. 
Consistent with our data, the activation of Notch1 signaling suppressed the expression of oxidative genes (Fig. 5). 
Together, these data show cell-autonomous effects of Notch1 signaling in hepatic lipid metabolism.
Gain and loss of Notch1 function affects lipid accumulation in adipocytes. To further explore 
the roles of Notch1 signaling in lipid accumulation, epididymal fat tissue was isolated from control and NAS 
mice, and lipolytic genes were subjected to real-time PCR analysis. The expression levels of Pparα and Cpt1a 
were increased in the white fat tissues of NAS mice (Fig. S5). The expression levels of other oxidative genes, 
Acsl1 and Ucp2, also showed a tendency to be increased in adipose tissues of NAS mice. To investigate the role 
of Notch1 in lipid accumulation in adipocytes, preadipocyte 3T3-L1 cells and mesenchymal C3H10T1/2 cells 
were used. To mimic Notch activation, C3H10T1/2 cells were infected with the NICD1-expressing retroviral 
plasmid pBabe-NICD or empty virus harboring control pBabe-Puro, and expression of oxidative genes was 
measured. The expression levels of the oxidative genes Acot1, Acsl1, Ucp2, Aox1, and Pparα were repressed by 
NICD1 expression in 3T3-L1 cells (Fig. S6). Interestingly, G6p expression was not repressed in preadipocytes, 
suggesting liver-specific regulation of G6p expression by Notch signaling. In parallel studies, NICD1 expression 
in C3H10T1/2 cells also exhibited similar effects on these oxidation genes (Fig. S6).
To examine the influence of NICD1 on lipid accumulation in adipocytes, NICD1-expressing and control cells 
were differentiated into adipocytes, and lipid accumulation was evaluated. Gain of function studies exhibited 
enhanced lipid accumulation with increased expression of adipocyte markers in both C3H10T1/2 and 3T3-L1 
cells (Fig. S7). The effects of Notch activation were also investigated in fully-differentiated C3H10T1/2 adipocytes. 
Consistently, forced expression of NICD1 in mature adipocytes also suppressed the expression of oxidative genes 
(Fig. S8).
Figure 4. Notch1 inhibition increases the expression of lipid oxidation genes and the rates of fatty acid 
oxidation in HepG2 cells. (A) The Notch signaling inhibitor DAPT increased the expression of oxidative genes 
but not lipogenic genes. Data shown represent the mean ± SEM, and are representative of three independent 
experiments. Mean with different letters in each sample indicates a significant difference (p < 0.05) by a Student-
Newman-Keuls test. (B) DAPT increased the rates of fatty acid oxidation. GW7647 (1 μ M), a PPARα agonist, 
was used as a control. Data shown represent the mean ± SD of quadruplicate determinations. Mean with 
different letters in each sample indicates a significant difference (p < 0.05) by a Student-Newman-Keuls test.
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To test the effect of Notch1 suppression on lipid accumulation, C3H10T1/2 cells expressing scrambled or 
Notch1 siRNAs were differentiated into adipocytes to induce lipid accumulation. Suppression of Notch1 expres-
sion decreased lipid accumulation as assessed by Oil red O staining (Fig. 6A,D). Consistent with previous 
reports20,21, cells transfected with two independent siRNAs were compared with scrambled siRNA-transfected 
cells and shown to successfully reduce Notch1 mRNA and protein expression (Fig. 6B,C). Furthermore, Notch1 
knockdown suppressed the expression of Pparγ and its downstream target genes aP2 and Cd36 (Fig. 6E). To 
further examine the roles of Notch1 signaling in fully differentiated adipocytes, Notch1 was blocked in mature 
adipocytes and the effects on lipid accumulation were assessed. Notch1 silencing in the differentiated C3H10T1/2 
adipocytes suppressed the expression of Pparγ and aP2 (Fig. 6F). Furthermore, DAPT treatment in differentiated 
adipocytes consistently decreased lipid accumulation and expression of Pparγ (Fig. 6G,H). Taken together, these 
data further corroborate the conserved role of Notch1 in lipid metabolism of hepatocytes and adipocytes.
Discussion
Hepatic steatosis, the most common form of liver disease, is characterized by high levels of triacylglycerol22. The 
regulatory mechanism of hepatic lipid catabolism is clearly an integral part of hepatic steatosis23. Lipid oxidation 
is controlled by various factors including PPARα and mitochondrial enzymes24. In contrast, lipogenesis is cata-
lyzed by SREBP-1c through the activation of FAS or ACC, and by PXR through PPARγ , CPT1, and SCD123,25,26. 
Other regulators such as CAR, LXR, and FXR have also been shown to regulate lipogenesis and beta-oxidation27. 
Thus, better understanding of the anabolic and catabolic pathways involved in lipid metabolism may provide 
another avenue for the intervention of liver disease.
Notch signaling is an evolutionarily conserved pathway that regulates various cell characteristics including cell 
differentiation and cell fate decision10. In the present study, we show that high-fat diet-induced hepatic lipid accu-
mulation was prevented in Notch1-deficient mice. These effects were associated with the induction of oxidative 
genes without clear effects on the expression of lipogenic genes. Furthermore, the regulation of oxidative genes by 
Notch1 signaling was consistently observed in adipose tissues. Gain of function reduced the expression of lipo-
lytic genes and lipid accumulation in adipocytes. These results indicate that Notch1 signaling plays a conserved 
role in lipid metabolism through actions on the expression of oxidative genes.
Pajvani et al., demonstrated that Notch inhibition in combination with Foxo deletion can suppress G6P 
expression, resulting in lower glucose levels14. In agreement, G6P induction was also detected in the regular 
chow diet-fed NAS mice. Pepck, Pc, and other critical genes in gluconeogenesis were not affected in livers from 
NAS mice or in Foxo and Notch1 haploinsufficient mice14. Thus, it is likely that lowered fasting glucose levels with 
increased insulin sensitivity may be attributed to the reduced expression of G6P. Whole body deficiency of G6P 
is characterized by hypoglycemia, hyperlipidemia, and hepatic disorder28,29. However, mice with liver-specific 
deletion of G6P exhibit normoglycemia in the fed state30. Thus, it seems questionable that G6pc alone in the liver 
is sufficient to lower glucose levels. Improvement of insulin sensitivity in Notch1-deficient mice could be the 
combined result of G6P and other effects on metabolism. In agreement with this hypothesis, previous studies 
have shown that Notch1 signaling can regulate the hepatic lipogenic program through actions on lipogenic gene 
expression16. Our current data reveal a previously unknown role for Notch1 signaling in the regulation of oxi-
dative genes. Reduced levels of G6P and increased expression of lipid oxidation genes may explain the increased 
insulin sensitivity observed in Notch1-deficient mice.
The present study employed mice ubiquitously expressing Notch1 antisense driven by the mouse mammary 
tumor virus long terminal repeat promoter. These mice were more insulin sensitive under high-fat diet-fed obese 
conditions compared with the wild type control mice. Similar to the effects in hepatocytes, the expression levels of 
oxidative genes in adipocytes were also increased. However, body weight gain, and food intake upon HFD feeding 
were not different in NAS mice compared with control mice, suggesting that enhanced insulin sensitivity in the 
NAS mice may be attributed to the actions of increased expression of hepatic oxidative genes. At present, the rea-
son for the differential impacts of Notch1 signaling on lipid accumulation in adipose tissue and liver are unclear. 
Figure 5. Notch1 activation decreases expression of lipid oxidation genes in HepG2 cells. Effect of Notch1 
signaling activation on oxidative genes in HepG2 cells. HepG2 cells were infected with lentivirus expressing 
NICD1 (NICD1) or control plasmid for 24 hours and gene expression was measured by real time PCR. Data are 
expressed as the mean ± SEM. Statistically significant differences in gene expression were determined relative to 
the control by a Student’s t-test (*p < 0.05; ***p < 0.0005).
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This may be due to the redundant effect of other Notch1 family members in adipose tissues. Indeed, Notch1, 
2, 3, and 4 are also expressed in fat tissues, suggesting potential redundant effects of Notch family members in 
fat tissues. Alternatively, liver-specific or adipose tissue-specific Notch1-deleted mice may exhibit tissue-specific 
metabolic effects on Notch1 signaling due to pleiotropic effects of Notch1 signaling in various tissues. Indeed, 
adipose-specific inactivation of Notch1 reduced fat mass and improved insulin sensitivity, corroborating the con-
served roles of Notch1 signaling in adipose tissues24. Thus, it is reasonable to suggest that Notch1 may play a 
conserved role in hepatocytes and adipocytes. However, liver-specific Notch1-deleted mice will be required to 
definitively show hepatocyte-specific effects of Notch1 signaling in fatty liver, as well as metabolic effects, in the 
future.
Our studies show that the Notch1 signaling pathway can regulate the expression of PPARα and lipid oxida-
tion genes. It remains to be determined how Notch1 signaling regulates the expression of these oxidative genes. 
One possibility is that Hes1 may function as an inhibitory mediator of Notch signaling. Previous studies have 
shown that Hes1, a direct target of Notch signaling, behaved as a transcriptional repressor through its binding to 
the E-Box region on target promoters25. Alternatively, NICD1 itself may regulate the expression of lipid oxida-
tion genes indirectly by modulating transcriptional activators or repressors that in turn affect the expression of 
oxidative genes. Indeed, this is the case in the regulation of G6p and Fas expression by NICD114,16. Determining 
whether there are direct effects of Hes1 and NICD on promoters of genes that encode lipid oxidation proteins is 
an intriguing avenue that should be explored in the future.
Figure 6. Knockdown of Notch1 by siRNAs decreases lipid accumulation in adipocytes. (A) C3H10T1/2 
and 3T3-L1 cells were transiently transfected with scrambled (scr) or siRNAs (#1 and #2) targeting Notch1, and 
induced to differentiate into adipocytes for 7 days. Lipid accumulation was assessed by Oil red O staining.  
(B,C) Two independent siRNAs effectively reduced Notch1 mRNA (B) and protein expression (C) in 
C3H10T1/2 cells. (D) Lipid accumulation was quantified by measuring the extracted Oil red O dye at 520 nM. 
(E) Expression of Pparγ and its target genes were measured by real-time PCR. (F) Fully-differentiated mature 
C3H10T1/2 adipocytes were transfected with scrambled (scr) or siRNAs (#1 and #2) targeting Notch1 and 
expression of Pparγ and aP2 were measured by real-time PCR. (G,H) Mature C3H10T1/2 adipocytes were 
treated with DAPT (20 μ M) for 48 hours, and lipid accumulation was assessed by Oil red O staining (G).  
(H) Pparγ expression was measured by real-time PCR. Data are expressed as the mean ± SEM. Mean with 
different letters in each sample indicates a significant difference (p < 0.05) by a Student-Newman-Keuls test.
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In the present study, we identified Notch1 signaling as a key determinant of triacylglycerol metabolism in 
response to a high fat diet, and we further revealed novel biological actions of Notch1 signaling pathways on the 
regulation of lipid oxidation. Additionally, our data suggest that inhibition of γ -secretase or the Notch signaling 
pathway could be a novel strategy to prevent and treat fatty liver disease associated with obesity.
Materials and Methods
Animal studies. All animal studies were carried out in accordance with, and with approval from, the 
Animal Research Committee of Sungkyunkwan University. Male C57BL/6 (8-week- old) mice were purchased 
from Central Lab Animal Inc. (Seoul, Korea) and housed in controlled temperature (24 ± 2 °C) and humidity 
(50 ± 10%) conditions under a 12-hour light and 12-hour dark cycle. Notch1 antisense transgenic (NAS) mice 
were generated as described previously12. These mice were individually housed and allowed free access to water 
and food (Solid feed 5L79, Orient. Co. LTD, Seoul, Korea). After an adaptation period of 1 week, 9-week-old mice 
were randomly assigned into four groups. One group of each C57BL/6 and NAS mice were fed ND (normal chow 
diet), while the second group of C57BL/6 and NAS mice were given a high-fat diet containing 60% fat (HFD; 
Research Diets Inc., NJ, USA) for 12 weeks. Body weight was measured twice per week, and food intake was 
determined three times per week.
For glucose tolerance tests, mice were fasted for 16 hours. Their glucose levels from tail-vein blood were deter-
mined prior to, and 30, 60, 90, and 120 minutes after i.p. injection of glucose (2 g/kg). For insulin tolerance tests, 
random fed-mice were injected i.p. with insulin (Humulin R, Eli Lilly, 1 U/kg). Glucose levels were determined 
prior to, and 30, 60, 120, 180, and 210 minutes after injection, using an Accu-Chek Active glucometer (Roche, 
Seoul, Korea). At the end of the experiments, mice were fasted for 16 hours and anesthetized by inhalation of 
ether followed by cardiac puncture. For histological studies, harvested tissues were fixed in 10% formaldehyde for 
2 days and embedded in paraffin. Paraffin blocks were sectioned at a thickness of 5 μ m and subjected to hematox-
ylin and eosin staining.
Cell culture. HepG2, C3H10T1/2, and 3T3-L1 cells were purchased from the American Type Culture 
Collection (Manassas, VA, USA). HepG2 cells were maintained in DMEM media supplemented with 10% fetal 
bovine serum (FBS) and 1% Pen/Strep. C3H10T1/2 and 3T3-L1 cells were maintained and differentiated into adi-
pocytes as previously described31. For differentiation, confluent cells were induced in DMEM supplemented with 
10% FBS, 1 μ M dexamethasone (Sigma, St. Louis, MO), 0.5 mM isobutyl-1-methylxanthine (Sigma), and 5 μ g/
ml insulin (Sigma) for 2 days. Every 2 days, cells were refreshed with media containing FBS and insulin. After 
6–8 days of differentiation, cells were fixed with 4% paraformaldehyde in PBS at room temperature for 4 hours, 
and stained with 0.5% Oil Red O (ORO, Sigma). ORO stained cells from at least two independent experiments 
were quantified by extracting dye with isopropanol. Absorbance was measured at 520 nm. Retroviral or lentivrial 
overexpression of NICD was performed using pBabe-puro and the packaging cell line of the Phoenix system as 
described previously31.
Protein expression. For Western blotting, cells were harvested in cell lysis buffer (1% Triton X-100 and 0.5% 
sodium deoxylcholate) with protease inhibitor cocktail tablets (11 836 153 001, Roche, Mannheim, Germany). 
Total cell lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to Amersham Hybond ECL nitrocellulose membranes (RPN 303D; GE Healthcare, Piscataway, 
NJ, USA) as described previously32. Anti-Notch1 (Sc 6014R) was obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Anti-IRS and pIRS1 (pTyr612) were purchased from Sigma-Aldrich (St. Louis, MO). Anti-AKT 
and pAKT(Ser473) were purchased from Cell Signaling (Beverly, MA). Anti-β -actin (A5316) antibody was pur-
chased from Santa Cruz Biotechnology. Visualized protein bands were quantified by densitometry using the 
Image J software (National Institute of Health, Bethesda, MD).
Quantitative real-time PCR. To isolate total RNA from mouse tissues, homogenized TRIzol sam-
ples were centrifuged and total RNAs were isolated. Isolated RNA was further cleaned by phenol-chloroform 
extraction, followed by ethanol precipitation. Total RNA (500 ng) and 300 pmol random primers were mixed 
and heated at 65 °C for 5 minutes, and reverse transcribed using RTase M-MLV buffer, dNTP mixture, and 
RTase M-MLV (2640A, Takara, Ohtsu, Japan) at 37 °C for 50 minutes. The cDNA was amplified by Thermal 
cycler dice (Takara) using Power SYBR Premix Ex Taq (RP041A, Takara) and specific primer sets as previ-
ously described and shown below31. Expression was normalized to 36B4. All real-time PCRs were performed 
at least twice.  cycle threshold (CT) was used to calculate the differences between the target CT value and 
the control (36B4) for each sample:  CT = CTtarget − CTcontrol. The relative expression level was calculated 
using 2−△CT. The oligonucleotide primer (Integrated DNA Technologies, San Diego, CA) sequences used for 
PCR were as follows: Pparα F, 5′ -atgccagtactgccgttttc-3′ and Pparα R, 5′ - ccgaatctttcaggtcgtgt-3′ ; Aox1 F, 5′ - 
caccattgccattcgataca-3′ and Aox1 R, 5′ - tgcgtctgaaaatccaaaatc-3′ ; Acot1 F, 5′ -gatcgcctcaaggatgttgt-3′ and Acot1 
R, 5′ - atgatctggggcttctcctt-3′ ; Cpt1a F, 5′ -gatgtggacctgcattcctt-3′ and Cpt1a R, 5′ -tcttgtaatgtgcgagctg-3′ ; Ucp2 
F, 5′ -acagccttctgcactcctg-3′ and Ucp2 R, 5′ - ggctgggagacgaaacact-3′ ; Acsl1 F, 5′ -accatgtacgatggcttcca-3′ and 
Acsl1 R, 5′ - tcatagggctggtttggctt-3′ ; Fas F, 5′ -gctgctgttggaagtcagc-3′ and Fas R, 5′ - agtgttcgttcctcggagtg-3′ ; Acc 
F, 5′ -gcagccctgggcacag-3′ and Acc R, 5′ -gggaatacccgtgggagtagtt-3′ ; G6p F, 5′ -tctgtcccggatctaccttg-3′ and G6p 
R, 5′ -gaaagtttcagccacagcaa-3′ ; Pc F, 5′ - cggcagggcggagctaacat-3′ and Pc R, 5′ -tttggggaggcaacaggggc-3′ ; Pepck F, 
5′ -atcatctttggtggccgtag-3′ and Pepck R, 5′ -catggctgctcctacaaaca-3′ ; Notch1 F, 5′ -ctggaccccatggacatc-3′ and Notch1 
R, 5′ - aggatgactgcacacattgc-3′ ; Pparγ F, 5′ -ccattctggcccaccaac-3′ and Pparγ R, 5′ - aatgcgagtggtcttccatca-3′ ; aP2 
F, 5′ -caccgcagacgacaggaag-3′ aP2 R, 5′ -gcacctgcaccagggc-3; Human PPARα F, 5′ -gcactggaactggatgacag-3′ and 
human PPARα R, 5′ -tttagaaggccaggacgatct-3′ ; human FAS F, 5′ -caggcacacacgatggac-3′ and human FAS R, 
5′ -cggagtgaatctgggttgat-3′ ; human ACC F, 5′ -gctggtccacatgaacagg-3′ and human ACC R, 5′ -gccttctggatattcaggacttt
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-3′ ; human SREBP-1c F, 5′ -cgctcctccatcaatgaca -3′ and human SREBP-1c R, 5′ - tgcgcaagacagcagattta-3′ ; 
human CPT1A F, 5′ -caatcggactctggaaacg-3′  and human CPT1A R, 5′ -ccgctgaccacgttcttc-3′ ; human 
UCP2 F, 5′ -tgaaagccaacctcatgaca-3′  and human UCP2 R, 5′ -gatgacagtggtgcagaagc-3′ ; human ACSL1 
F, 5′ -gcttttgtgaaagcaacagaga-3′  and human ACSL1 R, 5′ -ggcgagaggcaagaaagata-3′ ; human LCAD F, 
5′ -ggatctgtactccgcagctatt-3′ and LCAD R, 5′ -ctaaaacctgggcctgaaca-3′ ; human G6P F, 5′ -ccctgtaacctgtgagactgg-3′ 
and G6P R, 5′ -aaagagtagatgtgaccatcacgta-3′ ;
siRNA knockdown of Notch1. siRNA knockdown of Notch1 was carried out as described previ-
ously20. Two independent small interfering RNA (siRNA) sequences targeting Notch1 and a nonspecific neg-
ative control were purchased from Genolution Pharmaceutical Inc. (Seoul, Korea). Notch1 specific siRNA#1 
was sense 5′ - CCAACAAGGACAUGCAGAACAACAA UU-3′ . Notch1 specific siRNA#2 was sense 
5′ -UGAGACAGGCAACAGUGAAGAAGAA UU-3′ . The non-specific sequence for the negative control was 
sense 5′ -CCUCGUGCCGUUCCA UCAGGUAGUU-3′ . Cells were transfected with 20 pmol siRNA using 
Lipofectamine RNAiMAX (Invitrogen 13778-075) for 16 hours. After 48 hours, total RNA was extracted to meas-
ure the expression of oxidation genes by real-time PCR. To assess the effects on lipid accumulation, the trans-
fected cells were induced and differentiated into adipocytes for 7 days followed by ORO staining or total RNA 
extraction for real-time PCR. Transfections were carried out in triplicates.
Fatty acid oxidation. HepG2 cells were seeded in 24-well plates at a density of 2.5 × 105/well for 24 hours. 
Subsequently, the cells were loaded with free fatty acids (100 μ M palmitic acid and 100 μ M oleic acid) containing 
0.5% bovine serum albumin (BSA, Bovogen Biologicals, Melbourne, Australia) for 24 hours. The following day, 
cells were treated with DAPT (5, 10, or 20 μ M) or 1 μ M GW7647 in DMEM containing 0.45 mM [14C] palmitate 
(57 mCi/mM; Perkin Elmer) conjugated to 1 mg/ml FA-free BSA for a further 24 hours. The medium was removed 
to a sealed container and the l4CO2 was extracted by mixing with 0.5 ml 1 M NaOH and 0.5 ml concentrated HCl. 
The amount of 14CO2 was measured using a liquid scintillation counter. The total protein concentrations of cells 
were determined for normalization.
Statistical analysis. Data are presented as the mean ± SEM. Differences in gene expression and lipid accu-
mulation were analyzed using a two-tailed unpaired Student’s t–test or analysis of variance (ANOVA) followed 
by a Student-Newman-Keuls test. All computations were performed using statistical analysis software (PASW 
Statistics 17). Statistical significance was considered when a p value was less than 0.05.
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